ImmusanT

ImmusanT, Inc. was founded in 2010 as a biotechnology company focused on developing innovative diagnostic and therapeutic methods for autoimmune diseases such as celiac disease. It aims to improve the diagnosis and treatment management of celiac disease and other autoimmune conditions based on new discoveries in immunology. ImmusanT's revolutionary technology—the Epitope-Specific Immunotherapy (ESIT) platform—is based on patient genetic analysis. Its lead product, the celiac disease therapeutic vaccine Nexvax2®, is the first to demonstrate the ability to restore antigen-specific immune tolerance and suppress autoimmune responses in autoimmune diseases, achieving therapeutic effects.